9.39
前日終値:
$9.20
開ける:
$9.22
24時間の取引高:
3.01M
Relative Volume:
0.85
時価総額:
$1.04B
収益:
$631.73M
当期純損益:
$-239.78M
株価収益率:
-4.6485
EPS:
-2.02
ネットキャッシュフロー:
$-33.45M
1週間 パフォーマンス:
+7.07%
1か月 パフォーマンス:
+16.94%
6か月 パフォーマンス:
-29.61%
1年 パフォーマンス:
-63.31%
10 X Genomics Inc Stock (TXG) Company Profile
名前
10 X Genomics Inc
セクター
電話
(925) 401-7300
住所
6230 STONERIDGE MALL ROAD, PLEASANTON, CA
TXG を他の銘柄と比較する
株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
---|---|---|---|---|---|---|
![]()
TXG
10 X Genomics Inc
|
9.39 | 1.08B | 631.73M | -239.78M | -33.45M | -2.02 |
![]()
VEEV
Veeva Systems Inc
|
242.78 | 38.63B | 2.75B | 714.14M | 1.09B | 4.33 |
![]()
TEM
Tempus Ai Inc
|
65.49 | 10.62B | 803.32M | -709.10M | -212.68M | -7.8003 |
![]()
HQY
Healthequity Inc
|
98.23 | 7.82B | 1.15B | 96.70M | -161.99M | 1.09 |
![]()
DOCS
Doximity Inc
|
52.56 | 11.11B | 550.17M | 201.35M | 232.07M | 1.00 |
![]()
WAY
Waystar Holding Corp
|
39.34 | 6.92B | 906.14M | -52.62M | 89.62M | -0.3621 |
10 X Genomics Inc Stock (TXG) Upgrades & Downgrades
日付 | アクション | アナリスト | 評価の変更 |
---|---|---|---|
2025-02-13 | ダウングレード | Leerink Partners | Outperform → Market Perform |
2024-09-03 | 開始されました | Leerink Partners | Outperform |
2024-07-22 | アップグレード | Jefferies | Hold → Buy |
2024-07-18 | ダウングレード | JP Morgan | Overweight → Neutral |
2024-07-10 | ダウングレード | Deutsche Bank | Buy → Hold |
2024-06-27 | ダウングレード | Wolfe Research | Outperform → Peer Perform |
2024-06-25 | ダウングレード | Guggenheim | Buy → Neutral |
2024-06-03 | 再開されました | Jefferies | Hold |
2024-05-01 | ダウングレード | TD Cowen | Buy → Hold |
2023-12-14 | 開始されました | Guggenheim | Buy |
2023-12-13 | 開始されました | Wolfe Research | Outperform |
2023-12-12 | アップグレード | BofA Securities | Underperform → Neutral |
2023-07-05 | 再開されました | JP Morgan | Overweight |
2023-05-10 | 開始されました | Barclays | Overweight |
2023-03-31 | 開始されました | Stephens | Overweight |
2023-02-02 | 開始されました | UBS | Neutral |
2022-12-14 | 開始されました | Deutsche Bank | Buy |
2022-08-18 | ダウングレード | Goldman | Neutral → Sell |
2022-07-25 | 開始されました | Canaccord Genuity | Buy |
2022-07-15 | ダウングレード | BofA Securities | Neutral → Underperform |
2022-07-15 | ダウングレード | William Blair | Outperform → Mkt Perform |
2021-10-15 | 再開されました | Cowen | Outperform |
2021-09-14 | ダウングレード | BofA Securities | Buy → Neutral |
2021-03-15 | 開始されました | William Blair | Outperform |
2020-12-02 | 開始されました | Goldman | Neutral |
2020-09-09 | 開始されました | Morgan Stanley | Overweight |
2020-07-10 | 開始されました | Stifel | Buy |
2020-03-05 | 開始されました | Guggenheim | Buy |
2020-01-07 | 開始されました | Citigroup | Buy |
2019-10-07 | 開始されました | BofA/Merrill | Buy |
2019-10-07 | 開始されました | Cowen | Outperform |
2019-10-07 | 開始されました | JP Morgan | Overweight |
2019-09-24 | 開始されました | Evercore ISI | Outperform |
すべてを表示
10 X Genomics Inc (TXG) 最新ニュース
'Shooting ourselves in the foot': Trump administration cuts force East Bay’s 10x Genomics into layoffs - The Business Journals
NanoString to pay 10x Genomics $68m in global settlement - Life Sciences Intellectual Property Review
10x Genomics reaches settlement with Bruker - Medical Buyer
Stifel Financial Corp Raises Holdings in 10x Genomics, Inc. (NASDAQ:TXG) - Defense World
UBS Group Lowers 10x Genomics (NASDAQ:TXG) Price Target to $12.00 - Defense World
10x Genomics Reaches $68 Million Patent Settlement With Bruker - marketscreener.com
10x Genomics Settles Litigation with Bruker Corporation - TipRanks
10x Genomics settles patent dispute with Bruker for $68 million - Investing.com
10x Genomics Wins Massive $68M Settlement Plus Royalties in Major Patent Battle with Bruker - Stock Titan
All Ongoing Lawsuits Between Bruker And 10X Genomics To Be Withdrawn - marketscreener.com
Earnings Release: Here's Why Analysts Cut Their 10x Genomics, Inc. (NASDAQ:TXG) Price Target To US$12.96 - simplywall.st
10x Genomics (TXG) Price Target Reduced by UBS Amid Funding Chal - GuruFocus
Fierce Biotech Layoff Tracker 2025: Allogene cuts 28% of staff; Kyverna trims workforce by 16% - Fierce Biotech
10x Genomics, Bruker Strike Deal After $31M Patent Verdict - Law360
10x Genomics (TXG) Sees Price Target Lowered by UBS | TXG Stock News - GuruFocus
UPC battle between 10x Genomics and Curio Bioscience moves to next stage - JUVE Patent
UBS Adjusts Price Target on 10x Genomics to $12 From $14, Maintains Neutral Rating - marketscreener.com
Canaccord Adjusts 10x Genomics (TXG) Price Target Citing Market Uncertainty | TXG Stock News - GuruFocus
10x Genomics (NASDAQ:TXG) Price Target Lowered to $6.50 at The Goldman Sachs Group - Defense World
10x Genomics (NASDAQ:TXG) Price Target Cut to $15.00 by Analysts at Canaccord Genuity Group - Defense World
10x Genomics (TXG) Price Target Lowered by Canaccord Genuity | T - GuruFocus
Analyst Expectations For 10x Genomics's Future - Benzinga
JPMorgan Chase & Co. Cuts 10x Genomics (NASDAQ:TXG) Price Target to $9.00 - Defense World
10x Genomics, Inc. (NASDAQ:TXG) Just Reported Earnings, And Analysts Cut Their Target Price - Yahoo Finance
10x Genomics (NASDAQ:TXG) Shares Gap Up – Time to Buy? - Defense World
10x Genomics (NASDAQ:TXG) Receives Sell (E+) Rating from Weiss Ratings - Defense World
10x Genomics First Quarter 2025 Earnings: Beats Expectations - simplywall.st
30,005 Shares in 10x Genomics, Inc. (NASDAQ:TXG) Purchased by Raymond James Financial Inc. - Defense World
10x Genomics, Inc. (NASDAQ:TXG) Q1 2025 Earnings Call Transcript - Insider Monkey
JPMorgan Adjusts Price Target for 10x Genomics (TXG) Amid Market Concerns | TXG Stock News - GuruFocus
10x Genomics (TXG) Price Target Lowered to $9 by JP Morgan | TXG Stock News - GuruFocus
10x Genomics (TXG) Faces Price Target Reduction Amid Uncertain O - GuruFocus
Stifel Adjusts 10x Genomics (TXG) Price Target Amid Funding Conc - GuruFocus
Deutsche Bank Adjusts Price Target on 10x Genomics to $10 From $16, Maintains Hold Rating - marketscreener.com
Stifel Adjusts 10x Genomics (TXG) Price Target Amid Funding Concerns | TXG Stock News - GuruFocus
10x Genomics (TXG) Faces Price Target Reduction Amid Uncertain Outlook | TXG Stock News - GuruFocus
10x Genomics Inc (TXG) Q1 2025 Earnings Call Highlights: Navigat - GuruFocus
10x Genomics (NASDAQ:TXG) adds US$65m to market cap in the past 7 days, though investors from five years ago are still down 89% - simplywall.st
10x Genomics, Inc. SEC 10-Q Report - TradingView
10x Genomics Reports First Quarter 2025 Financial Results - BioSpace
10x Genomics Inc (TXG) Q1 2025 Earnings Call Highlights: Navigating Challenges with Strategic ... - Yahoo Finance
10x Genomics Inc (TXG) Q1 2025 Earnings Call Highlights: Navigating Challenges with Strategic Initiatives - GuruFocus
10x Genomics CEO Calls NIH The 'Foundational Jewel' Of Biomedical Progress, Says 40% To 50% Of Revenue Supported By Academic And Government Research Funding — Pulls Full Year Revenue Guidance - Benzinga
10x Genomics: Q1 Earnings Snapshot - CTPost
Compared to Estimates, 10x Genomics (TXG) Q1 Earnings: A Look at Key Metrics - Yahoo Finance
10x Genomics’s (NASDAQ:TXG) Q1: Strong Sales But Quarterly Revenue Guidance Significantly Misses Expectations - Yahoo Finance
10x Genomics (TXG) Reports Q1 Loss, Tops Revenue Estimates - Yahoo Finance
10x Genomics Announces Workforce Reduction to Cut Costs - TipRanks
10x Genomics Inc Q1 2025 Earnings: EPS of -$0.28 Beats Estimate, Revenue Surges to $154.9 Million - GuruFocus
Earnings Flash (TXG) 10x Genomics Posts Q1 Loss $-0.28 Per Share, vs. FactSet Est of $-0.47 - marketscreener.com
10x Genomics (NASDAQ:TXG) shareholders have endured a 90% loss from investing in the stock five years ago - Yahoo Finance
10 X Genomics Inc (TXG) 財務データ
収益
当期純利益
現金流量
EPS
10 X Genomics Inc (TXG) インサイダートレーディング
インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
---|---|---|---|---|---|---|---|
Saxonov Serge | Chief Executive Officer |
Feb 28 '25 |
Sale |
10.63 |
7,942 |
84,393 |
871,540 |
大文字化:
|
ボリューム (24 時間):